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Summary
Conflicting findings regarding the association between protein Z
and atherosclerotic disease have been reported.The aim of this
case-control study was to evaluate the role of protein Z in a pe-
ripheral localization of atherosclerosis. We studied protein Z
levels in 120 patients (102 male,18 female;median age:75 years)
admitted to the Unit of Vascular Surgery of the University of
Florence with a clinical manifestation of peripheral arterial dis-
ease (PAD), and in 360 healthy subjects selected to be com-
parable to the patients group in terms of age and gender.Protein
Z levels were found to be significantly (p < 0.05) lower in PAD
patients [1,594 (89–3,635) ng/ml] compared to the healthy con-
trol group [1,728 (300–3,736) ng/ml].A logistic regression analy-
sis showed, at univariate analysis, a significantly increased risk of
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PAD in patients with low levels of protein Z (<5
th
percentile of
our control group: < 601 ng/ml) (OR: 5.72, 95%CI 3.07–10.66; p
< 0.0001). After adjustment for age, gender and traditional car-
diovascular risk factors the association was confirmed (OR:
5.83, 95%CI 2.83–12.01; p < 0.0001). Moreover, a significant as-
sociation between low protein Z levels and clinical severity of
the disease, evaluated through Fontaine’s stages, was reported
after adjustment for age, gender, and traditional cardiovascular
risk factors (general linear model, p for trend: 0.03). In con-
clusion, our data shows an association between low protein Z
levels and the occurrence of PAD.These findings provide evi-
dence for the role of protein Z in the pathogenesis of the
atherosclerotic disease.
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Introduction
Protein Z is a vitamin K-dependent plasma coagulation factor
that acts as a cofactor for the inactivation of activated factor X by
forming a complex with a specific plasma protein Z-dependent
protease inhibitor (1).
Over the last few years protein Z has been evaluated in differ-
ent prothrombotic conditions, ranging from fetal loss to retinal
occlusion (2, 3). Furthermore, besides its physiological function,
a role for protein Z on the pathogenesis of atherosclerotic disease
has also been hypothesised by Greten et al., who demonstrated
protein Z to be present in the microvascular endothelial cells of
the atherosclerotic vessels of patients with peripheral athero-
sclerotic vascular lesions (4). To date, some clinical studies on
the possible association between protein Z and atherosclerotic
disease have been performed, but the studies reported conflicting
findings, limited mainly to cardiac and cerebral ischemic dis-
eases (5–12). We previously reported a role for low protein Z
plasma levels in the occurrence of a thrombotic event (9) in dif-
ferent phases of coronary atherosclerotic activity, so supposing a
pathological link between protein Z and atherosclerosis apart
from the acute thrombotic event (10). However, to the best of our
knowledge, no data are available regarding the role of protein Z
in clinical manifestations of atherosclerosis other than the coron-
ary and cerebral. Therefore, we designed this case-control study
to investigate the possible association between protein Z levels
and peripheral arterial disease (PAD).
Methods
Study population
The study population consisted of 132 patients recruited
amongst all the patients with symptoms or signs suggestive of
the presence of PAD. These patients were subsequently admitted
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to the Unit of Vascular Surgery of the University of Florence,
Italy to be clinically evaluated for a possible surgical interven-
tion. To avoid the variables known to influence protein Z plasma
levels, five out of 132 patients (3.8%) were excluded because
they tested positive for antiphospholipid antibodies, three (2.3%)
for renal insufficiency (creatinine levels >1.5 mg/dl) and four
(3%) for the presence of factorV Leiden mutation.Therefore, the
final study population consisted of 120 [102 male, 18 female;
median age: 75 years (49–93)] adult patients. None of the pa-
tients were under anticoagulant treatment. PAD was diagnosed
when patients had typical symptoms of intermittent claudi-
cation, i.e. cramping pain of the calves or buttocks during exer-
cise, and ankle-brachial index at rest less than 0.90, calculated
according to the recommendations of the American Heart As-
sociation (13).
All patients underwent clinical and instrumental evaluation
to investigate other manifestations of atherosclerotic disease. In
particular, a cardiologic evaluation including electrocardiogram
and echocardiogram was conducted. Moreover, in patients show-
ing symptoms possibly related to ischemic heart disease further
investigations were performed (echocardiogram on drug-in-
duced stress testing, myocardial scintigraphy, and/or coronary
angiography). Furthermore, duplex scanning with colour coded
echo flow imaging on carotid arteries was conducted.
Fontaine levels were assigned as follows: stage 2a, mild
claudication with a walking distance > 200 meters; stage 2b, se-
vere claudication with a walking distance < 200 meters; stage 3,
rest pain.
The patients were compared to 360 clinically healthy sub-
jects [median age: 74 years (37–87); 306 male, 54 female] re-
cruited from a population study conducted in Florence, Italy be-
tween 2002 and 2004. Clinically healthy subjects were selected
to be comparable in age and gender with the patients group. We
used a structured questionnaire to identify disease-free controls
and to exclude subjects who were suspected of having any form
of vascular disease. The subjects were considered to have hyper-
tension if they had been diagnosed as hypertensives according to
the guidelines of The European Society of Hypertension/Euro-
pean Society of Cardiology (14) or were taking antihypertensive
drugs. Dyslipidemia was defined according to theThird report of
the National Cholesterol Education Program (NCEP) (15) and
diabetes in agreement with the American Diabetes Association
(16). A positive family history was defined as the presence of at
least one first-degree relative who had developed cardiovascular
disease before the age of 55 years for men and 65 years for
women. All subjects gave informed consent; the study complies
with the Declaration of Helsinki and was approved by the local
ethics committee.
Laboratory measurement
Blood samples were collected from the antecubital vein into
evacuated plastic tubes (Vacutainer) containing 0.109 M sodium
citrate, on the morning after a period of overnight fasting. Plas-
ma samples, obtained by centrifuging at 3,000 g for 10 minutes
at 4°C, were stored in aliquots at – 80 °C until analysis.
Protein Z antigen levels in the plasma were measured using a
commercial enzyme-linked immunoadsorbent assay (Roche
Diagnostics) as previously described (10). The intra-assay coef-
ficient of variation is 4.9% and the interassay coefficient of vari-
ation is 8.4%.
Statistical analysis
Statistical analysis was performed using the SPSS (Statistical
Package for Social Sciences Inc., Chicago, IL, USA) software
for Windows (Version 13.0). Due to its skewed distribution, pro-
tein Z levels were log-analysed and back transformed for data
presentation. Results are expressed as median and range. The
non-parametric Mann-Whitney test for unpaired data was used
for comparison between single groups and the chi
2
-test was used
to test for proportions. In order to analyse the relationship be-
tween protein Z and PAD we performed an univariate logistic re-
gression analysis with low protein Z levels defined as protein Z
levels below the 5
th
percentile of our control population (< 601
ng/ml). Following this, a multivariate model was performed in
Figure 1: Protein Z levels according to
the number of traditional cardiovascular
risk factors in both populations of pa-
tients and healthy control subjects
(n=480)*.Values are expressed as geometric
mean and (95% CI). *General linear model ad-
justed for age and gender.
order to evaluate the association between protein Z < 5
th
percen-
tile and the disease after adjustment for traditional cardiovascu-
lar risk factors (smoking habit, hypertension, dyslipidemia, and
diabetes). Moreover, the concurrent presence of protein Z levels
< 5
th
percentile and traditional cardiovascular risk factors was
also investigated through a multivariate model with the use of in-
teraction terms. In addition, to investigate the possible associ-
ation between protein Z levels and the number of traditional car-
diovascular risk factors, as well as the clinical severity of the dis-
ease (evaluated using the clinical Fontaine’s stages) a general lin-
ear model was conducted, and data was expressed as the geo-
metric mean and 95% confidence interval (CI). The odds ratio
(OR) with 95% CI was indicated, and a p-value < 0.05 was con-
sidered to indicate statistical significance.
Results
Demographic and clinical characteristics of the study population
are summarized in Table 1. In PAD patients, all the traditional
cardiovascular risk factors, except for familial history of cardio-
vascular disease, were more prevalent compared to clinically
healthy subjects.
Protein Z plasma levels were found to be significantly (p <
0.05) lower in PAD patients [1,594 (89–3,635) ng/ml] compared
to clinically healthy subjects [1,728 (300–3,736) ng/ml]. In par-
ticular, low protein Z levels, defined as plasma levels below the
5
th
percentile of our control group (601 ng/ml), were found in 29
out of 120 (24.2%) patients and in 19 out of 360 (5.3%) controls
(p < 0.0001).
In order to test the possible association between low levels of
protein Z and the occurrence of PAD we performed a logistic re-
gression analysis which showed, at the univariate analysis, an in-
creased risk of PAD for patients with protein Z levels below the
5
th
percentile of our control group (OR: 5.72, 95%CI
3.07–10.66; p < 0.0001). At the multivariate analysis, performed
after adjustment for age, gender and traditional cardiovascular
risk factors, the association of protein Z levels below 601 ng/ml
and PAD was confirmed (OR: 5.83, 95%CI 2.83–12.01; p <
0.0001).
Subsequently, we analysed the possible relationship between
protein Z and the traditional cardiovascular risk factors. The
whole population of patients and clinically healthy subjects was
grouped on the basis of the number of the traditional cardiovas-
cular risk factors and significantly (p for trend: 0.01) decreasing
levels of protein Z, according to the number of traditional cardio-
vascular risk factors, were observed (Fig. 1). Similarly, a signifi-
cant (p < 0.0001) increasing prevalence of subjects with protein
Z < 5
th
percentile among different numbers of traditional cardio-
vascular risk factors has been observed [0 risk factor: 17/225
(7.6%); 1 risk factor: 9/120 (7.5%); 2 risk factors: 16/101
(15.8%); 3 risk factors: 6/31 (19.4%)]. Indeed, the concurrent
presence of low levels of protein Z and two of the main tradi-
tional cardiovascular risk factors in the patients, such as smoking
habit (n=18) and hypertension (n=19) increased the susceptibil-
ity to the disease, at the multivariate analysis [smoking habit OR:
3.61 (95%CI 2.24–5.82), p < 0.0001; low levels of protein Z and
smoking habit OR: 12.84 (95%CI 4.61–35.80), p < 0.0001], [hy-
pertension OR: 2.67 (95% CI 1.66–4.30), p < 0.0001; low levels
of protein Z and hypertension OR: 13.94 (95%CI 4.89–39.73), p
< 0.0001].
Finally, in order to evaluate the possible association between
protein Z levels and the clinical progression of PAD (defined by
Fontaine’s clinical stages), a general linear model was conducted,
after adjustment for age, gender, and traditional cardiovascular
risk factors. A significant decreasing trend (p = 0.03) for protein
Z levels according to the clinical progression of the disease, was
observed (Fig. 2). Moreover, a significant (p = 0.08) increasing
prevalence of patients with protein Z levels < 5
th
percentile ac-
cording to Fontaine’s clinical stages was reported [stage 2a: 1/13
(7.7%); stage 2b: 26/100 (26%); stage 3: 2/7 (28.6%)].
Discussion
In this study we report a possible involvement of protein Z in the
occurrence of PAD. Indeed, patients with PAD had significantly
lower levels of protein Z in comparison to clinically healthy sub-
jects, and an increased risk of PAD for patients with protein Z
levels below the 5
th






Age, years * 75 (49–93) 74 (37–87) 0.4
Male gender, n (%) 102 (85) 306 (85) -
Hypertension, n (%) 66 (55) 112 (31.1) < 0.0001
Smoking habit, n (%) 65 (54.2) 92 (25.6) < 0.0001
Dyslipidemia, n (%) 65 (54.2) 79 (21.9) < 0.0001
Diabetes, n (%) 16 (13.3) 14 (3.9) 0.0002
Familial history of
CVD, n (%)
18 (15) 44 (12.2) 0.4
* Median and (range). CVD: cardiovascular disease.
Table 1: Demographic characteristics and traditional cardiovas-
cular risk factors for patients and controls.
Figure 2: Protein Z levels according to Fontaine’s stages
(n=120).Values are expressed as geometric mean and (95% CI). * Gen-
eral linear model adjusted for age, gender, smoking habit, hypertension,
dyslipidemia, and diabetes.
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Furthermore, decreasing levels of protein Z according to the
number of cardiovascular risk factors and with the clinical pro-
gression of PAD was evidenced. To the best of our knowledge,
this is the first study that has analyzed the association between
protein Z levels and PAD, thus providing new insights into the re-
lationship between protein Z and the atherosclerotic process.
Protein Z levels were found to be associated with the occur-
rence of ischemic stroke (5–8) and coronary heart disease (9–10)
in some but not in all of the studies (11–12).These contrasting re-
sults might be due to the different times of examination for pro-
tein Z after the acute ischemic event as well as to the presence of
subjects with a previous vascular event present in the control
group and to the different study populations investigated. In our
previous studies we reported a significant and independent as-
sociation between low protein Z plasma levels and the occur-
rence of acute coronary syndromes as well as a persistence of
this association also in a stable phase of coronary atherosclerotic
disease (9–10). On the other hand, however, we were unable to
find a significant difference between patients in the acute phase
and patients in the chronic phase of the disease. This allowed us
to hypothesise that protein Z is somehow linked to the athero-
sclerotic process apart from the acute thrombotic event.
In the present study, to confirm previous findings and sup-
port this hypothesis, we decided to study PAD as a model of
atherosclerosis that reflects a more extended involvement of
vessels. As a result, we found a significant association between
the severity of PAD, evaluated through the clinical Fontaine’s
stages, and decreasing protein Z plasma levels. Furthermore, we
were able to find a significant association between protein Z lev-
els and the number of atherosclerotic risk factors as well as a sig-
nificantly increased risk of PAD for subjects with the concurrent
presence of low protein Z levels and two traditional cardiovascu-
lar risk factors, such as smoking habit and hypertension. These
results reinforce the hypothesis of the involvement of low protein
Z levels in the pathogenesis of atherosclerotic disease, with a
strict relationship with arterial risk factors.
The reasons why protein Z was found to be lower in athero-
sclerotic patients as compared to clinically healthy controls are
currently unresolved. On the one hand, low protein Z could be as-
cribed to an increased consumption due to the chronic activation
of the coagulative cascade; on the other hand, it’s possible that
low protein Z is linked to the severity of atherosclerotic disease,
by reflecting the endothelial dysfunction detectable in these pa-
tients.
Atherosclerosis is a systemic degenerative process that be-
gins at an early age and that is significantly precipitated by the
presence of risk factors. Atherosclerosis-related endothelial
damage provides a surface for continuous thrombus formation,
fibrinolysis, plaque remodelling and atherosclerotic progres-
sion. Protein Z, representing a thrombophilic factor involved in
the pathogenesis of atherothrombotic disease may act in combi-
nation with the other traditional cardiovascular risk factors in de-
termining the atherosclerotic risk burden.
Some limitations can be identified in the present study.
Firstly, because of its case-control design, the study is unable to
determine if low protein Z levels are causally related to the pres-
ence and severity of PAD. Secondly, in our study we analysed
protein Z below the 5
th
percentile of our control group and not
decreasing levels of the protein since our previous studies
showed a possible threshold effect of protein Z in the occurrence
of the disease. Thirdly, protein Z was measured as antigen levels,
thus corresponding to the circulating levels and not to the activ-
ity of the protein.
However, we observed for the first time a significant associ-
ation between low protein Z levels and the occurrence, as well as
the severity, of PAD. These results may be helpful for identifying
the real involvement of protein Z in the development of athero-
sclerosis and stimulate the need for further studies to confirm
these preliminary findings.
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